OBJECTIVE: To summarize proceedings of a workshop convened to discuss the current state of science in the disease of osteoarthritis (OA), identify the knowledge gaps, and examine the developmental and regulatory challenges in bringing these products to market. DESIGN: Summary of the one-day workshop held virtually on June 22nd, 2021. RESULTS: Speakers selected by the Planning Committee presented data on the current approach to assessment of OA therapies, biomarkers in OA drug development, and the assessment of disease progression and long-term benefit. CONCLUSIONS: Demonstrated by numerous failed clinical trials, OA is a challenging disease for which to develop therapeutics. The challenge is magnified by the slow time of onset of disease and the need for clinical trials of long duration and/or large sample size to demonstrate the effect of an intervention. The OA science community, including academia, pharmaceutical companies, regulatory agencies, and patient communities, must continue to develop and test better clinical endpoints that meaningfully reflect disease modification related to long-term patient benefit.
OBJECTIVE: To summarize proceedings of a workshop convened to discuss the current state of science in the disease of osteoarthritis (OA), identify the knowledge gaps, and examine the developmental and regulatory challenges in bringing these products to market. DESIGN: Summary of the one-day workshop held virtually on June 22nd, 2021. RESULTS: Speakers selected by the Planning Committee presented data on the current approach to assessment of OA therapies, biomarkers in OA drug development, and the assessment of disease progression and long-term benefit. CONCLUSIONS: Demonstrated by numerous failed clinical trials, OA is a challenging disease for which to develop therapeutics. The challenge is magnified by the slow time of onset of disease and the need for clinical trials of long duration and/or large sample size to demonstrate the effect of an intervention. The OA science community, including academia, pharmaceutical companies, regulatory agencies, and patient communities, must continue to develop and test better clinical endpoints that meaningfully reflect disease modification related to long-term patient benefit.
Authors: M Kretzschmar; M C Nevitt; B J Schwaiger; G B Joseph; C E McCulloch; T M Link Journal: Osteoarthritis Cartilage Date: 2019-02-23 Impact factor: 6.576
Authors: L Gossec; S Paternotte; J F Maillefert; C Combescure; P G Conaghan; A M Davis; K-P Gunther; G Hawker; M Hochberg; J N Katz; M Kloppenburg; K Lim; L S Lohmander; N N Mahomed; L March; K Pavelka; L Punzi; E M Roos; L Sanchez-Riera; J A Singh; M E Suarez-Almazor; M Dougados Journal: Osteoarthritis Cartilage Date: 2010-10-31 Impact factor: 6.576
Authors: Susmita Kashikar-Zuck; Stacy R Flowers; Daniel Strotman; Soumitri Sil; Tracy V Ting; Kenneth N Schikler Journal: Arthritis Care Res (Hoboken) Date: 2013-03 Impact factor: 4.794
Authors: Eduardo Ferriolli; Richard J E Skipworth; Paul Hendry; Angela Scott; Jacob Stensteth; Max Dahele; Lucy Wall; Carolyn Greig; Marie Fallon; Florian Strasser; Tom Preston; Kenneth C H Fearon Journal: J Pain Symptom Manage Date: 2012-01-24 Impact factor: 3.612
Authors: V B Kraus; B Burnett; J Coindreau; S Cottrell; D Eyre; M Gendreau; J Gardiner; P Garnero; J Hardin; Y Henrotin; D Heinegård; A Ko; L S Lohmander; G Matthews; J Menetski; R Moskowitz; S Persiani; A R Poole; J-C Rousseau; M Todman Journal: Osteoarthritis Cartilage Date: 2011-03-23 Impact factor: 6.576
Authors: Laure Gossec; Gillian Hawker; Aileen M Davis; Jean Francis Maillefert; L Stefan Lohmander; Roy Altman; Jolanda Cibere; Philip G Conaghan; Marc C Hochberg; Joanne M Jordan; Jeffrey N Katz; Lyn March; Nizar Mahomed; Karel Pavelka; Ewa M Roos; Maria E Suarez-Almazor; Gustavo Zanoli; Maxime Dougados Journal: J Rheumatol Date: 2007-06 Impact factor: 4.666
Authors: M Lotz; J Martel-Pelletier; C Christiansen; M-L Brandi; O Bruyère; R Chapurlat; J Collette; C Cooper; G Giacovelli; J A Kanis; M A Karsdal; V Kraus; W F Lems; I Meulenbelt; J-P Pelletier; J-P Raynauld; S Reiter-Niesert; R Rizzoli; L J Sandell; W E Van Spil; J-Y Reginster Journal: Ann Rheum Dis Date: 2013-07-29 Impact factor: 19.103
Authors: Felix Eckstein; Jeffrey L Kraines; Aida Aydemir; Wolfgang Wirth; Susanne Maschek; Marc C Hochberg Journal: Ann Rheum Dis Date: 2020-02-25 Impact factor: 19.103
Authors: Jason S Kim; Silvana Borges; Daniel J Clauw; Philip G Conaghan; David T Felson; Thomas R Fleming; Rachel Glaser; Elizabeth Hart; Marc Hochberg; Yura Kim; Virginia B Kraus; Larissa Lapteva; Xiaojuan Li; Sharmila Majumdar; Timothy E McAlindon; Ali Mobasheri; Tuhina Neogi; Frank W Roemer; Rebecca Rothwell; Robert Shibuya; Jeffrey Siegel; Lee S Simon; Kurt P Spindler; Nikolay P Nikolov Journal: Semin Arthritis Rheum Date: 2022-07-14 Impact factor: 5.431